Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/Rosuvastatin + Telmisartan in Patients with Essential Hypertension and Primary Hypercholesterolemia
NCT04659070Phase 3Unknown
- Sponsor
- Hanlim Pharm
- Start
- Jul 2020
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of ezetimibe, rosuvastatin, telmisartan in essential hypertension, hypercholesterolemia, sponsored by Hanlim Pharm. Status: unknown.
02
Drugs
ezetimiberosuvastatintelmisartan
03
Conditions
essential hypertensionhypercholesterolemia
Beyond the preview
Go deeper on NCT04659070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659070.